EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Rhabdomyosarcoma - Pipeline Review, H2 2015

  • ID: 3502770
  • Report
  • October 2015
  • 103 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • EpiZyme, Inc.
  • Morphotek, Inc.
  • Novartis AG
  • Noxxon Pharma AG
  • MORE
Rhabdomyosarcoma - Pipeline Review, H2 2015

Summary

The report ‘Rhabdomyosarcoma - Pipeline Review, H2 2015’, provides an overview of the Rhabdomyosarcoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rhabdomyosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Rhabdomyosarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Rhabdomyosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rhabdomyosarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Rhabdomyosarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Rhabdomyosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • EpiZyme, Inc.
  • Morphotek, Inc.
  • Novartis AG
  • Noxxon Pharma AG
  • MORE
List of Tables

List of Figures

Introduction

REPORT COVERAGE

Rhabdomyosarcoma Overview

Therapeutics Development

Pipeline Products for Rhabdomyosarcoma - Overview

Pipeline Products for Rhabdomyosarcoma - Comparative Analysis

Rhabdomyosarcoma - Therapeutics under Development by Companies

Rhabdomyosarcoma - Therapeutics under Investigation by Universities/Institutes

Rhabdomyosarcoma - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Rhabdomyosarcoma - Products under Development by Companies

Rhabdomyosarcoma - Products under Investigation by Universities/Institutes

Rhabdomyosarcoma - Companies Involved in Therapeutics Development

Bellicum Pharmaceuticals, Inc.

Boehringer Ingelheim GmbH

Celgene Corporation

EpiZyme, Inc.

Merrimack Pharmaceuticals, Inc.

Morphotek, Inc.

Novartis AG

Noxxon Pharma AG

Shionogi & Co., Ltd.

Rhabdomyosarcoma - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

afatinib dimaleate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cell Therapy for GD2 Expressing Solid Tumors - Drug Profile

Product Description

Mechanism of Action

R&D Progress

celyvir - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile

Product Description

Mechanism of Action

R&D Progress

everolimus - Drug Profile

Product Description

Mechanism of Action

R&D Progress

irinotecan sucrosofate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NOXS-93 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ontuxizumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

paclitaxel albumin bound - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pazopanib hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

S-588410 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

tazemetostat - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Rhabdomyosarcoma - Recent Pipeline Updates

Rhabdomyosarcoma - Dormant Projects

Rhabdomyosarcoma - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Rhabdomyosarcoma, H2 2015

Number of Products under Development for Rhabdomyosarcoma - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Rhabdomyosarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015

Rhabdomyosarcoma - Pipeline by Boehringer Ingelheim GmbH, H2 2015

Rhabdomyosarcoma - Pipeline by Celgene Corporation, H2 2015

Rhabdomyosarcoma - Pipeline by EpiZyme, Inc., H2 2015

Rhabdomyosarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015

Rhabdomyosarcoma - Pipeline by Morphotek, Inc., H2 2015

Rhabdomyosarcoma - Pipeline by Novartis AG, H2 2015

Rhabdomyosarcoma - Pipeline by Noxxon Pharma AG, H2 2015

Rhabdomyosarcoma - Pipeline by Shionogi & Co., Ltd., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Rhabdomyosarcoma Therapeutics - Recent Pipeline Updates, H2 2015

Rhabdomyosarcoma - Dormant Projects, H2 2015

Rhabdomyosarcoma - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Rhabdomyosarcoma, H2 2015

Number of Products under Development for Rhabdomyosarcoma - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015
Note: Product cover images may vary from those shown
3 of 4
Bellicum Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
Celgene Corporation
EpiZyme, Inc.
Merrimack Pharmaceuticals, Inc.
Morphotek, Inc.
Novartis AG
Noxxon Pharma AG
Shionogi & Co., Ltd.
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll